Update on Federal Workplace Drug Testing: What You Need to Know for 2026

If your organization relies on federal workplace drug testing programs, staying up to date with the latest regulations is critical. On March 13, 2026, the Department of Health and Human Services (HHS) and the Substance Abuse and Mental Health Services Administration (SAMHSA) published an official notification regarding the authorized testing panels for Schedule I and II drugs.

Here is a digestible breakdown of what this update means for your compliance programs:

The Big Takeaway: Status Quo Maintained

The most important news from this publication is what isn't changing.

• The Department has made absolutely no revisions to the current drug testing panels for urine and oral fluid.

  
  

• There are no changes to the required nomenclature (analyte names and abbreviations) used for laboratory and Medical Review Officer Reports.

  
  

• The analytes and test cutoffs remain exactly the same as those published previously in January 2025.

  
  

• The only actual updates made by the Department were minor edits to footnotes 1 and 2 within the drug testing panels to improve clarity and correctness.

  
  

What Drugs Are on the Authorized Panels? For both urine and oral fluid testing, the authorized federal testing panels continue to cover the following substances:

• Marijuana (THC)

  
  

• Cocaine

  
  

• Codeine and Morphine

  
  

• Hydrocodone and Hydromorphone

  
  

• Oxycodone and Oxymorphone

  
  

• 6-Acetylmorphine

  
  

• Phencyclidine (PCP)

  
  

• Fentanyl

  
  

• Amphetamine and Methamphetamine

  
  

• MDMA and MDA

  
  

A Note on Biomarker Testing

If your organization has been waiting for widespread biomarker testing to become standardized, that time has not yet arrived.

• SAMHSA has not yet authorized routine testing for any biomarker in either urine or oral fluid.

  
  

• Currently, the Department does not require HHS-certified test facilities to implement authorized biomarker tests.

  
  

• If a Medical Review Officer requests a biomarker test, HHS-certified laboratories must submit supporting documentation and assay validation records to the National Laboratory Certification Program to request special authorization for that specific test.

  
  

Bottom Line For compliance officers, HR professionals, and federal contractors, your current drug testing protocols remain fully compliant. Because the current authorized panels and nomenclature tables remain in effect, you will not need to overhaul your testing limits or reporting procedures at this time.